推荐产品
方案
≥90% (HPLC)
质量水平
表单
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
amber
溶解性
DMSO: 50 mg/mL
运输
ambient
储存温度
2-8°C
SMILES字符串
Ic1ncnc(c1)c2ccccc2
InChI
1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H
InChI key
ZTCJXHNJVLUUMR-UHFFFAOYSA-N
一般描述
A cell-permeable iodo-pyrimidine compound that covalently modifies MIF N-terminal proline and exhibits higher MIF inhibitory potency than ISO-1 (Cat. No. 475837) in cell-free dopachrome tautomerase activity assays (IC50 ~5 vs. 50 µM, respectively, using recombinant human MIF) as well as in cell-based migration assays (50% vs 0% inhibition with respective inhibitor at 10 µM) and anchorage-independent growth (57% vs 0% inhibition with respective inhibitor at 10 µM) using human lung adenocarcinoma A549. Also shown to reduce A549 cellular active Rac1 population (50 µM, 16 h) in vitro and effectively decrease liver tautomerase activity by 50% in mice (1 mg/animal/day or ~50 mg/kg/day via i.p.) in vivo.
A cell-permeable iodo-pyrimidine compound that covalently modifies MIF N-terminal proline and exhibits higher MIF inhibitory potency than ISO-1 (Cat. No. 475837) in cell-free dopachrome tautomerase activity assays (IC50 ~5 vs. 50 µM, respectively, using recombinant human MIF) as well as in cell-based migration assays (50% vs 0% inhibition with respective inhibitor at 10 µM) and anchorage-independent growth (57% vs 0% inhibition with respective inhibitor at 10 µM) using human lung adenocarcinoma A549. Also shown to reduce A549 cellular active Rac1 population (50 µM, 16 h) in vitro and effectively decrease liver tautomerase activity by 50% in mice (1 mg/animal/day or ~50 mg/kg/day via i.p.) in vivo.
包装
Packaged under inert gas
警告
Toxicity: Standard Handling (A)
其他说明
Winner, M., et al. 2008. Cancer Res.68, 7253.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
储存分类代码
11 - Combustible Solids
WGK
WGK 3
Ricardo A de Azevedo et al.
Oncoimmunology, 9(1), 1846915-1846915 (2020-12-22)
Immune checkpoint blockade (ICB) has demonstrated an impressive outcome in patients with metastatic melanoma, yet, durable complete response; even with Ipilimumab/Nivolumab combo are under 30%. Primary and acquired resistance in response to ICB is commonly due to a tumor immune
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门